Financial Data and Key Metrics Changes - The company reported sales of approximately $2.3 million in Q2 of the previous year, which increased to $9.3 million in Q3, and further to $13.8 million in Q4. In Q1 of the current year, sales reached $11.3 million, reflecting a transition to an internalized sales force [5][6][7]. Business Line Data and Key Metrics Changes - The company has launched a product for COVID-19 pre-exposure prophylaxis under emergency use authorization, with a focus on internalizing the sales force to drive growth [2][6]. - The sales force was fully trained and operational by the end of Q1, leading to positive trends in new account orders and interactions with healthcare providers [8][9]. Market Data and Key Metrics Changes - The COVID-19 therapy market was valued at over $9 billion last year, with the company currently capturing only a small share of the potential patient population eligible for its product [11][12]. - The company has been added to the NCCN guidelines for certain B-cell lymphomas, indicating a growing recognition of its product as a standard of care [12]. Company Strategy and Development Direction - The company is focusing on the development of next-generation antibodies, particularly VYD2311, which is expected to be more potent and have a longer half-life than existing products [17][24]. - There is an emphasis on expanding into other at-risk populations beyond the immunocompromised, including healthcare workers [25]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing relevance of their targeted epitopes against evolving SARS-CoV-2 variants, supported by extensive variant monitoring and surveillance [28][30]. - The company anticipates updates on RSV and measles programs by the end of 2025, indicating a strategic focus on addressing unmet medical needs in these areas [41]. Other Important Information - The FDA denied the treatment request for PEMGARDA, but the company sees this as an opportunity to engage with the new administration for future treatment indications [17][19]. - The company is open to business development discussions, including potential partnerships or government collaborations [46]. Q&A Session Summary Question: Can you provide updates on the sales force and its impact? - The internalized sales force has shown promising trends in new account orders and healthcare provider interactions, contributing to a return to growth [8][9]. Question: What is the company's strategy regarding payer reimbursement? - The company is covered by Medicare and Medicaid under EUA, with positive outcomes from major commercial payers [10]. Question: How does the company view the future of monoclonal antibodies in COVID treatment? - There is potential for monoclonal antibodies in treating COVID-19, especially for immunocompromised patients [14][15]. Question: What are the next steps for the measles and RSV programs? - The company anticipates updates on both programs by the end of 2025, with a focus on identifying candidates [41][42]. Question: How does the company plan to engage with regulatory agencies? - The company plans to engage with the FDA regarding treatment indications for next-generation antibodies and seeks alignment on expectations for monoclonal antibodies [18][20].